Summary

Eligibility
for males ages 6-11 (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Craig McDonald

Description

Summary

To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every two weeks in ambulatory subjects with Duchenne muscular dystrophy (age 6 to <12 years).

Official Title

A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)

Details

This is a global, randomized, double-blind, trial of pamrevlumab or placebo in combination with systemic corticosteroids in subjects with Duchenne muscular dystrophy, aged 6 to <12 years (ambulatory subjects only). Approximately 70 subjects will be randomized at a 1:1 ratio to Arm A (pamrevlumab + systemic deflazacort or equivalent potency of corticosteroids administered orally) or Arm B (placebo+ systemic deflazacort or equivalent potency of corticosteroids administered orally), respectively. Subjects must be fully informed of the potential benefits of approved products and make an informed decision when participating in a clinical trial in which they could be randomized to placebo. Subjects will be randomized in a 1:1 ratio to one of the two study treatment arms; pamrevlumab or placebo. Randomization will be stratified by exon 44 deletion. The main study has three study periods: - Screening period: Up to 4 weeks - Treatment period: 52 weeks - Safety Follow-up period/final assessment: A visit 28 days (+/- 3 Days) and a final safety follow-up phone call 60 days (+ 3 Days) after the last dose Each subject will receive pamrevlumab or placebo at 35 mg/kg every 2 weeks for up to 52 weeks. Subjects who complete 52 weeks of treatment may be eligible for an open-label extension (OLE), offering extended treatment with pamrevlumab. Subjects who discontinue study treatment for any reason should be encouraged to return to the investigative site to complete final safety and efficacy assessments.

Keywords

Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy, DMD Muscular Dystrophies Muscular Dystrophy, Duchenne Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Genetic Diseases, Inborn Genetic Diseases, X-Linked Pamrevlumab

Eligibility

You can join if…

Open to males ages 6-11

Age, and consent:

  1. Males at least 6 to <12 years of age at screening initiation
  2. Written consent by legal guardian as per regional/ country and/or IRB/IEC requirements

DMD diagnosis:

  1. Medical history includes diagnosis of DMD and confirmed Duchenne mutation using a validated genetic test.

Pulmonary criteria:

  1. Average (of screening and day 0) percent predicted FVC above 45%
  2. On a stable dose of systemic corticosteroids for a minimum of 6 months, with no substantial change in dosage for a minimum of 3 months (except for adjustments for changes in body weight) prior to screening. Corticosteroid dosage should be in compliance with the DMD Care Considerations Working Group recommendations (e.g. prednisone or prednisolone 0.75 mg/kg per day or deflazacort 0.9 mg/kg per day) or stable dose. A reasonable expectation is that dosage and dosing regimen would not change significantly for the duration of the study.

Performance criteria:

  1. Able to complete 6MWD test with a distance of at least 270M but no more than 450M on two occasions within 3 months prior to Randomization with ≤10% variation between these two tests.
  2. Able to rise (TTSTAND) from floor in <10 seconds (without aids/orthoses) at screening visit.
  3. Able to undergo MRI test for the lower extremities vastus lateralis muscle.

Vaccination:

  1. Received pneumococcal vaccine (PPSV23) (or any other pneumococcal polysaccharide vaccine as per national recommendations) and is receiving annual influenza vaccinations.

Laboratory criteria:

  1. . Adequate renal function: cystatin C ≤1.4 mg/L
  2. . Adequate hematology and electrolytes parameters:
  3. Platelets >100,000/mcL
  4. Hemoglobin >12 g/dL
  5. Absolute neutrophil count >1500 /μL
  6. Serum calcium (Ca), potassium (K), sodium (Na), magnesium (Mg) and phosphorus (P) levels are within a clinically accepted range
  7. . Adequate hepatic function:
  8. No history or evidence of liver disease
  9. Gamma glutamyl transferase (GGT) ≤3x upper limit of normal (ULN)
  10. Total bilirubin ≤1.5xULN

You CAN'T join if...

General Criteria:

  1. Concurrent illness other than DMD that can cause muscle weakness and/or impairment of motor function
  2. Severe intellectual impairment (eg, severe autism, severe cognitive impairment, severe behavioral disturbances) preventing the ability to perform study assessments in the Investigator's judgment
  3. Previous exposure to pamrevlumab
  4. BMI ≥40 kg/m2 or weight >117 kg
  5. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies
  6. Exposure to any investigational drug (for DMD or not), in the 30 days prior to screening initiation or use of approved DMD therapies (e.g., eteplirsen, ataluren, golodirsen) within 5 half-lives of screening, whichever is longer with the exception of the systemic corticosteroids, including deflazacort

Pulmonary and Cardiac criteria:

  1. Requires ≥16 hours continuous ventilation
  2. Poorly controlled asthma or underlying lung disease such as bronchitis, bronchiectasis, emphysema, recurrent pneumonia that in the opinion of the investigator might impact respiratory function
  3. Hospitalization due to respiratory failure within the 8 weeks prior to screening
  4. . Severe uncontrolled heart failure (NYHA Classes III-IV), including any of the following:
  5. Need for intravenous diuretics or inotropic support within 8 weeks prior to screening
  6. Hospitalization for a heart failure exacerbation or arrhythmia within 8 weeks prior to screening
  7. . Arrhythmia requiring anti-arrhythmic therapy
  8. . Any other evidence of clinically significant structural or functional heart abnormality

Clinical judgment:

  1. . The Investigator judges that the subject will be unable to fully participate in the study and complete it for any reason, including inability to comply with study procedures and treatment, or any other relevant medical, surgical or psychiatric conditions

Locations

  • University of California Davis Children's Hospital not yet accepting patients
    Sacramento California 95817 United States
  • Children's Hospital Los Angeles accepting new patients
    Los Angeles California 90027 United States

Lead Scientist at UC Davis

  • Craig McDonald
    Professor, Physical Medicine and Rehabilitation. Authored (or co-authored) 202 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
FibroGen
Links
Sign up for this study
ID
NCT04632940
Phase
Phase 3
Study Type
Interventional
Last Updated